p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture.
Aline Rangel-PozzoSamuel BoothPak Lok Ivan YuMadhurendra SinghGalina SelivanovaSabine MaiPublished in: Journal of clinical medicine (2020)
The TP53 gene is a key tumor suppressor. Although the tumor suppressor p53 was one of the first to be characterized as a transcription factor, with its main function potentiated by its interaction with DNA, there are still many unresolved questions about its mechanism of action. Here, we demonstrate a novel role for p53 in the maintenance of nuclear architecture of cells. Using three-dimensional (3D) imaging and spectral karyotyping, as well as super resolution microscopy of DNA structure, we observe significant differences in 3D telomere signatures, DNA structure and DNA-poor spaces as well gains or losses of chromosomes, between normal and tumor cells with CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-deleted or wild-type TP53. Additionally, treatment with Nutlin-3 results in differences in nuclear architecture of telomeres in wild-type but not in p53 knockout MCF-7 (Michigan Cancer Foundation-7) cells. Nutlin-3 binds to the p53-binding pocket of mouse double minute 2 (MDM2) and blocks the p53-MDM2 interaction. Moreover, we demonstrate that another p53 stabilizing small molecule, RITA (reactivation of p53 and induction of tumor cell apoptosis), also induces changes in 3D DNA structure, apparently in a p53 independent manner. These results implicate p53 activity in regulating nuclear organization and, additionally, highlight the divergent effects of the p53 targeting compounds Nutlin-3 and RITA.
Keyphrases
- circulating tumor
- single molecule
- wild type
- cell free
- small molecule
- genome wide
- transcription factor
- induced apoptosis
- high resolution
- nucleic acid
- cell cycle arrest
- magnetic resonance imaging
- squamous cell carcinoma
- magnetic resonance
- optical coherence tomography
- oxidative stress
- genome editing
- circulating tumor cells
- copy number
- high speed
- photodynamic therapy
- binding protein
- pi k akt